Literature DB >> 23421851

Peyronie's disease and mechanotransduction: an in vitro analysis of the cellular changes to Peyronie's disease in a cell-culture strain system.

Eric Chung1, Ling De Young, Matthew Solomon, Gerald B Brock.   

Abstract

INTRODUCTION: Penile traction therapy (PTT) has gained considerable popularity as a noninvasive treatment option in Peyronie's disease (PD) to improve penile curvature and length. However the exact mechanism of action of PTT is unknown and as yet unproven. AIM: Using a cyclic strain culture system, we investigate the cellular changes to the tunical tissues following equibiaxial tractional forces. The observed protein alteration following mechanical traction should replicate the changes observed in tunical tissue following PTT.
METHODS: Flexcell FX-5000(TM) Tension Plus system (Flexcell International Corporation, McKee-sport, PA, USA) is a pressurized chamber system that allows for sustained and dynamic application of hydrostatic pressure to cellular culture. Primary cell cultures from PD and normal tunical tissue (control) were sub-cultured on BioFlex-ProNectin plate 1 × 106 (Flexcell International Corporation, Hillsborough, NC, USA) for 24 hours and exposed to Flexcell sinusoidal strain of 18% at 1 Hz (strained group) on the biaxial plates for 24 hours under 37 °C in a 5% CO2 atmosphere. MAIN OUTCOMES MEASURES: Immunohistochemistry (IHC) stains and Western blot assays between strained and nonstrained (control) cells.
RESULTS: Significant increase in smooth muscle α-actin, β-catenin, and Hsp 47 proteins were measured in the PD group compared with control group. IHC staining revealed a decrease in α-actin staining while Western blot assay showed an increase in metalloproteinase-8 expression with no measured change in β-catenin level in the strained PD group.
CONCLUSIONS: This novel study of cells derived from diseased and normal human tunica albuginea cultured in a mechanical strained environment provides good scientific evidence for the use of penile traction device in Peyronie's plaque remodeling.
© 2013 International Society for Sexual Medicine.

Entities:  

Mesh:

Year:  2013        PMID: 23421851     DOI: 10.1111/jsm.12082

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  7 in total

Review 1.  Contemporary Review of Peyronie's Disease Treatment.

Authors:  Edward Capoccia; Laurence A Levine
Journal:  Curr Urol Rep       Date:  2018-05-17       Impact factor: 3.092

2.  2018 Canadian Urological Association guideline for Peyronie's disease and congenital penile curvature.

Authors:  Anthony J Bella; Jay C Lee; Ethan D Grober; Serge Carrier; Francois Benard; Gerald B Brock
Journal:  Can Urol Assoc J       Date:  2018-02-22       Impact factor: 1.862

Review 3.  Intralesional collagenase Clostridium histolyticum in the management of Peyronie's disease: current best practice.

Authors:  Daniel J Cwikla; Faysal A Yafi
Journal:  Ther Adv Urol       Date:  2018-02-08

Review 4.  Indications and characteristics of penile traction and vacuum erection devices.

Authors:  Abida Sultana; Peter Grice; Josip Vukina; Ian Pearce; Vaibhav Modgil
Journal:  Nat Rev Urol       Date:  2021-11-11       Impact factor: 14.432

5.  Intralesional collagenase Clostridium histolyticum vs. verapamil injections in males with Peyronie's Disease: A prospective, matched-pair, non-blinded, randomised clinical study comparing clinical outcomes and patient satisfaction rates.

Authors:  Eric Chung; Juan Wang
Journal:  Investig Clin Urol       Date:  2022-09

Review 6.  The pathophysiology of Peyronie's disease.

Authors:  Ahmed I El-Sakka; Emre Salabas; Murat Dinçer; Ates Kadioglu
Journal:  Arab J Urol       Date:  2013-08-07

Review 7.  The Use of Penile Traction Devices for Peyronie's Disease: Position Statements from the European Society for Sexual Medicine.

Authors:  Borja García-Gómez; Antonio Aversa; Manuel Alonso-Isa; Arie Parnham; Ege Can Serefoglu; Giovanni Corona; Carlo Bettocchi; Yacov Reisman; Marta Skrodzka; Javier Romero-Otero
Journal:  Sex Med       Date:  2021-07-15       Impact factor: 2.523

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.